
ZyVersa Therapeutics Investor Relations Material
Latest events

AGM 2025
ZyVersa Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ZyVersa Therapeutics Inc
Access all reports
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company dedicated to developing innovative drugs for renal and inflammatory diseases with significant unmet medical needs. The company leverages advanced proprietary technologies to create first-in-class therapeutics. Its key product candidates include the Cholesterol Efflux Mediator VAR 200, which is being developed to remove excess cholesterol from the kidneys' filtration system to prevent damage and reduce proteinuria, potentially treating conditions like diabetic kidney disease, focal segmental glomerulosclerosis (FSGS), and Alport syndrome. Another major candidate is the Inflammasome ASC Inhibitor IC 100, a monoclonal antibody designed to inhibit inflammation by targeting the ASC protein, which is implicated in a variety of inflammatory conditions, including neuroinflammatory diseases like Parkinson’s and Alzheimer’s, as well as metabolic complications related to obesity. The company is headquartered in Weston, Florida, and its shares are listed on the NASDAQ.
Latest articles
)
Luca de Meo: Succeeding Pinault as the New CEO of Kering
Luca de Meo's leap from auto to luxury marks a bold new chapter as he becomes the first non-Pinault CEO to lead the Kering empire.
16 Jun 2025
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
Ticker symbol
ZVSA
Country
🇺🇸 United States